Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

Health Economics Review

Table 1 Mean values of probabilities employed in the decision tree

Strategy	Probabilities of relapse over 52 weeks	Probabilities of discontinuation of treatment over 52 weeks		Probabilities that treatment is best in reducing relapse over 52 weeks (reassessed excluding zotepine)	Probabilities of adverse events				Probabilities of Diabetes Mellitus complications
		Intolerable side effects	Other reasons		EPS	Weight gain	Glucose intolerance	Diabetes Mellitus	Amputation	Fatal myocardial infarction	Non-fatal myocardial infarction	Non-fatal stroke	Heart failure	Ischaemic heart disease
Amisulpride	0.2988	0.0554	0.2435	0.084	0.3163	0.3175	0.2381	0.0317	0.0023	0.0042	0.0130	0.0039	0.0040	0.0157
Aripiprazole	0.2742	0.1582	0.3520	0.119	0.2258	0.1516	0.1167	0.0156
Haloperidol	0.3317	0.0922	0.2516	0.035	0.5367	0.2000	0.1500	0.0200
Olanzapine	0.1996	0.0783	0.2730	0.152	0.2336	0.4172	0.3129	0.0417
Paliperidone ER	0.1625	0.3287	0.3848	0.525	0.2569	0.2123	0.1592	0.0212
Risperidone	0.2761	0.0994	0.1761	0.086	0.3546	0.2141	0.1606	0.0214

EPS: Extra-Pyramidal Symptoms)
ER: Extended-Release
Annual probability of transition of impaired glucose intolerance to diabetes = 0.0196

ISSN: 2191-1991